PL3335725T3 - Epitopy PDS5A jako induktory odporności - Google Patents

Epitopy PDS5A jako induktory odporności

Info

Publication number
PL3335725T3
PL3335725T3 PL16835086.6T PL16835086T PL3335725T3 PL 3335725 T3 PL3335725 T3 PL 3335725T3 PL 16835086 T PL16835086 T PL 16835086T PL 3335725 T3 PL3335725 T3 PL 3335725T3
Authority
PL
Poland
Prior art keywords
pds5a
epitopes
immunity inducers
inducers
immunity
Prior art date
Application number
PL16835086.6T
Other languages
English (en)
Inventor
Akira Kurihara
Fumiyoshi Okano
Original Assignee
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Inc. filed Critical Toray Industries, Inc.
Publication of PL3335725T3 publication Critical patent/PL3335725T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL16835086.6T 2015-08-10 2016-08-05 Epitopy PDS5A jako induktory odporności PL3335725T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015158539 2015-08-10
PCT/JP2016/073077 WO2017026389A1 (ja) 2015-08-10 2016-08-05 免疫誘導剤

Publications (1)

Publication Number Publication Date
PL3335725T3 true PL3335725T3 (pl) 2024-07-22

Family

ID=57984435

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16835086.6T PL3335725T3 (pl) 2015-08-10 2016-08-05 Epitopy PDS5A jako induktory odporności

Country Status (16)

Country Link
US (2) US11510971B2 (pl)
EP (1) EP3335725B1 (pl)
JP (1) JP7181676B2 (pl)
KR (1) KR102679914B1 (pl)
CN (1) CN107847573B (pl)
AU (1) AU2016306408B2 (pl)
BR (1) BR112018001542A2 (pl)
DK (1) DK3335725T5 (pl)
ES (1) ES2977955T3 (pl)
FI (1) FI3335725T3 (pl)
HU (1) HUE066530T2 (pl)
MX (1) MX392412B (pl)
PL (1) PL3335725T3 (pl)
PT (1) PT3335725T (pl)
RU (1) RU2758112C2 (pl)
WO (1) WO2017026389A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3335725T5 (da) * 2015-08-10 2024-10-07 Toray Industries PDS5A-epitoper som immunitetsinduktorer
EP3706784A4 (en) 2017-11-08 2021-12-01 BioNTech US Inc. COMPOSITIONS AND METHODS OF MANUFACTURING T-CELLS
TWI777160B (zh) * 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法
CN113527440B (zh) * 2021-08-10 2022-12-23 昆明医科大学 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009065A1 (fr) 1995-09-07 1997-03-13 Japan Tobacco Inc. Remede contre maladies auto-immunes
AU2002305151A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
US7842467B1 (en) * 2005-05-12 2010-11-30 Celera Corporation Breast disease targets and uses thereof
WO2009012460A1 (en) 2007-07-19 2009-01-22 Health Research, Inc. Survivin peptides as cancer vaccines
WO2009054710A1 (es) 2007-10-23 2009-04-30 Villegas Lopez Saul Dispositivo lijador de interiores y/o exteriores cilindricos
CN104873962B (zh) * 2007-10-25 2019-04-26 东丽株式会社 免疫诱导剂
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
WO2011027807A1 (ja) 2009-09-03 2011-03-10 東レ株式会社 免疫誘導剤
CN103547284B (zh) * 2011-05-19 2015-11-25 东丽株式会社 免疫诱导剂
RU2634862C2 (ru) * 2011-05-19 2017-11-07 Торэй Индастриз, Инк. Агент, индуцирующий иммунитет
DK3335725T5 (da) * 2015-08-10 2024-10-07 Toray Industries PDS5A-epitoper som immunitetsinduktorer
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction

Also Published As

Publication number Publication date
DK3335725T3 (da) 2024-04-02
MX2018001298A (es) 2018-05-17
WO2017026389A1 (ja) 2017-02-16
ES2977955T3 (es) 2024-09-03
RU2021127767A (ru) 2021-11-23
EP3335725A1 (en) 2018-06-20
RU2018107330A (ru) 2019-09-12
FI3335725T3 (fi) 2024-04-23
CA2993427A1 (en) 2017-02-16
DK3335725T5 (da) 2024-10-07
MX392412B (es) 2025-03-24
RU2758112C2 (ru) 2021-10-26
RU2018107330A3 (pl) 2020-01-31
PT3335725T (pt) 2024-05-08
US20180200356A1 (en) 2018-07-19
EP3335725B1 (en) 2024-02-28
US11510971B2 (en) 2022-11-29
BR112018001542A2 (pt) 2018-11-06
AU2016306408B2 (en) 2021-02-11
HUE066530T2 (hu) 2024-08-28
US20230190899A1 (en) 2023-06-22
AU2016306408A1 (en) 2018-02-22
KR20180037999A (ko) 2018-04-13
EP3335725A4 (en) 2019-03-27
JP7181676B2 (ja) 2022-12-01
CN107847573B (zh) 2021-12-31
JPWO2017026389A1 (ja) 2018-05-24
KR102679914B1 (ko) 2024-07-01
CN107847573A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
GB201508950D0 (en) Methods
GB201521751D0 (en) Novel uses
IL253635A0 (en) Cyclopropanebenzofuranyl pyridopyrazinedione type compounds
GB201508927D0 (en) Methods
GB2539126B (en) Interface
PL3335725T3 (pl) Epitopy PDS5A jako induktory odporności
DK3330264T3 (en) Pyridin substitueret 2-aminopyridin proteinkinase-inhibitorkrystal
GB201601250D0 (en) No details present
GB201415419D0 (en) Tracer
GB2540162B (en) Tracers
GB201518940D0 (en) Novel safe
GB201517135D0 (en) Interface design
GB201519665D0 (en) Interface
GB2530305B (en) Tracers
GB201707862D0 (en) Tracers
GB201810841D0 (en) Interface design
GB201418365D0 (en) Tracers
GB201409664D0 (en) Tracers
AU5592P (en) Lanmichigan Mandevilla boliviensis x sanderi
GB201512620D0 (en) Immune status
GB201614041D0 (en) Not present
GB201510045D0 (en) 3D orinted zoetropic jewlery
AU2014325V (en) MALOF003 Philodendron bipinnatifidum
GB201509453D0 (en) Tracers
GB201520989D0 (en) Novel methods